Meeting
2016 ASCO Annual Meeting
Effect of cancer vaccine formulation on synergy with anti-CTLA-4 and anti-PD-L1 checkpoint blockade therapy of cancer.
Authors
Yared Hailemichael
The University of Texas MD Anderson Cancer Center, Houston, TX
Yared Hailemichael , Tihui Fu , Amber Woods , Kimberly Schluns , Victor H Engelhard , Padmanee Sharma , Willem W Overwijk
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Vaccines
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3094)
DOI
10.1200/JCO.2016.34.15_suppl.3094
Abstract #
3094
Poster Bd #
416
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.
First Author: Sofie Kirial Mørk
Poster
2022 ASCO Annual Meeting
A novel polymeric peptide delivery platform and association with targeted co-delivery of antigens and STING agonists with antitumor immune response.
First Author: Max Mu Wang
Poster
2021 ASCO Annual Meeting
Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.
First Author: Yoshiki Arakawa
Poster
2021 ASCO Annual Meeting
A phase 1b study of personalized neoantigen vaccine plus pembrolizumab in adults with advanced cancer.
First Author: Aaron Miller